Iron chelation therapy in myelodysplastic syndromes: evidence-based rationale and comparison of guidelines

2010 ◽  
Vol 3 (1) ◽  
pp. 11-15
Author(s):  
Michael Pfeilstöcker
Keyword(s):  
Myelodysplastic Syndromes ◽  
Chelation Therapy ◽  
Iron Chelation ◽  
Evidence Based ◽  
Iron Chelation Therapy

The Role of Iron Chelation Therapy for Patients With Myelodysplastic Syndromes

2011 ◽  
Vol 9 (1) ◽  
pp. 65-75 ◽  
Author(s):  
David P. Steensma
Keyword(s):  
Iron Overload ◽  
Myelodysplastic Syndromes ◽  
Chelation Therapy ◽  
Iron Chelation ◽  
Clinical Intervention ◽  
Iron Chelation Therapy ◽  
Careful Attention ◽  
High Quality ◽  
Iron Parameters

The appropriate role of iron chelation therapy in the management of patients with myelodysplastic syndromes (MDS) is currently controversial. Some investigators interpret data to indicate that careful attention to iron parameters, with early initiation of iron chelation in patients with evidence suggesting transfusion-associated iron overload, is an important component of high-quality MDS patient care. Other physicians are more skeptical, noting that chelation can be cumbersome or costly, has associated risks, and has not yet been shown to reduce morbidity or mortality in the MDS setting. This article reviews the extent to which iron chelation therapy might be either an important clinical intervention in MDS or a distraction from more pressing clinical concerns.

scholarly journals Iron chelation therapy in myelodysplastic syndromes: where do we stand?

2013 ◽  
Vol 6 (4) ◽  
pp. 397-410 ◽  
Author(s):  
Mhairi Mitchell ◽  
Steven D Gore ◽  
Amer M Zeidan
Keyword(s):  
Myelodysplastic Syndromes ◽  
Chelation Therapy ◽  
Iron Chelation ◽  
Iron Chelation Therapy

scholarly journals Iron Chelation Therapy in Myelodysplastic Syndromes

2010 ◽  
Vol 2010 ◽  
pp. 1-8 ◽  
Author(s):  
Emanuela Messa ◽  
Daniela Cilloni ◽  
Giuseppe Saglio
Keyword(s):  
Iron Overload ◽  
Myelodysplastic Syndromes ◽  
Chelation Therapy ◽  
Therapeutic Option ◽  
Iron Chelation ◽  
Iron Chelation Therapy ◽  
Hematopoietic Stem ◽  
The Future ◽  
Clinical Consequences ◽  
Transfusion Dependency

Myelodysplastic syndromes (MDS) are a heterogeneous disorder of the hematopoietic stem cells, frequently characterized by anemia and transfusion dependency. In low-risk patients, transfusion dependency can be long lasting, leading to iron overload. Iron chelation therapy may be a therapeutic option for these patients, especially since the approval of oral iron chelators, which are easier to use and better accepted by the patients. The usefulness of iron chelation in MDS patients is still under debate, mainly because of the lack of solid prospective clinical trials that should take place in the future. This review aims to summarize what is currently known about the incidence and clinical consequences of iron overload in MDS patients and the state-of the-art of iron chelation therapy in this setting. We also give an overview of clinical guidelines for chelation in MDS published to date and some perspectives for the future.

Sign in / Sign up

Export Citation Format

Share Document